Register
Login:
Share:
Email Facebook Twitter

Josh Mahony from IG sums up the forces driving markets and currencies Watch here

Leading commentator Josh Mahony from IG - are we seeing a US$ revaluation?


Immupharma Share Price (IMM)



Share Price Information for Immupharma (IMM)


Share Price: 48.125Bid: 47.25Ask: 49.00Change: 0.00 (0.00%)No Movement on Immupharma
Spread: 1.75Spread as %: 3.70%Open: 46.00High: 48.00Low: 44.00Yesterday’s Close: 48.125

Immupharma Plc Ord 10P

Immupharma is listed in the FTSE AIM All-Share
Immupharma is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
48.125

Share Price SpacerBid
47.25

Share Price SpacerAsk
49.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
372,153

Share Price SpacerOpen
46.00

Share Price SpacerHigh
48.00

Share Price SpacerLow
44.00

Share Price SpacerClose
48.125

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 132.52m £63.61m 5,000

52 Week High 69.00 52 Week High Date 17-FEB-2017
52 Week Low 33.00 52 Week Low Date 9-NOV-2016

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
79 185,814 166,339 -10.573 -4.54 0.00 0.00


London South East Users info for Immupharma




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

18-Aug-17
17:03:18
44.75
927
Sell* 
47.25
49.00
414.83
Trade Type:
Ordinary
Bargain conditions apply

18-Aug-17
17:03:16
44.75
9,073
Sell* 
47.25
49.00
4,060
Trade Type:
Ordinary
Bargain conditions apply

18-Aug-17
17:00:37
45.25
20,000
Sell* 
47.25
49.00
9,050
Trade Type:
Ordinary
Bargain conditions apply




View more Immupharma trades >>

Directors Deals for Immupharma (IMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
30-Apr-15Notification of Holding
Trade Notifier Information for Immupharma
Stephane Robert George Mery held the position of Non-Executive Director at Immupharma at the time of this trade.
 Stephane Robert George Mery
002259
24-Jan-13Sell
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
57GBX62,1690
24-Jan-12Buy
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
80GBX62,1690
View more Immupharma directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Fri 20:21RidiculousThanks48.125No Opinion
Thanks for your input , folks. I've held Immupharma for quite some time, partly because of some of their innovative approach. I've been building up my holding and WANT them to succeed. The timing was what made me actually raise the subject. Onwards and , hopefully, upwards!
Fri 20:01PinWizRE: Suspicious?48.125No Opinion
OB it makes sense to me all IMO of course!
Fri 19:32oilbaggerRE: Suspicious?48.125Strong Buy
PinWiz - looks like a few of us have jumped to the same conclusions. Hope there is something in it.
Should be an interested start to next week.
Fri 19:30oilbaggerRE: Suspicious?48.125Strong Buy
See Rule 17 or paragraph (g) of Schedule 2 in

http://www.londonstockexchange.com/companies-and-advisors/aim/advisers/aim-notices/aimrulesforcompaniesjan16.pdf

However there is guidance notes for Schedule 2 on page 49 which says

(g) Whilst directors are usually only required to disclose directorships held over the last five
years, the requirements contained in (g)(iv)-(vii) which relate to bankruptcies, receiverships and
liquidations are not limited to the last five years.

Hence, I… Read More
Fri 19:29oilbaggerRE: Suspicious?48.125Strong Buy
For McCarthy appointment the RNS (30/9/2015) is below. It just lists companies where he was a director 5 years ago but mentions Alizyme in the introduction. Perhaps Alizyme wasn't mentioned because it was back in Dec 2009. Could be the AIM rule has changed or was interpreted incorrectly (was within 12 month of his appointment)

Mr McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is currently Chairman and Non-Executive… Read More
Fri 19:27oilbaggerRE: Suspicious?48.125Strong Buy
The announcement in the RNS is not that important in itself (public knowledge and discussed on advfn before - this should have been included when McCarthy was appointed in 2015 - just carelessness ) but
I have to agree with waterloo1 - there is a possibility that Due Diligence (DD) as part of a deal or takeover has brought this up.
Before everyone gets too exciting it might be just IMM advisors making sure everything is in good shape before negotiations begin.

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Immupharma (IMM) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.